Browse ADAM2

Summary
SymbolADAM2
NameADAM metallopeptidase domain 2
Aliases PH-30b; PH30; CT15; cancer/testis antigen 15; FTNB; fertilin beta; CRYN1; CRYN2; PH30-beta; fertilin subunit ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Single-pass type I membrane protein.
Domain PF08516 ADAM cysteine-rich
PF00200 Disintegrin
PF01562 Reprolysin family propeptide
PF01421 Reprolysin (M12B) family zinc metalloprotease
Function

Sperm surface membrane protein that may be involved in sperm-egg plasma membrane adhesion and fusion during fertilization. Could have a direct role in sperm-zona binding or migration of sperm from the uterus into the oviduct. Interactions with egg membrane could be mediated via binding between its disintegrin-like domain to one or more integrins receptors on the egg. This is a non catalytic metalloprotease-like protein.

> Gene Ontology
 
Biological Process GO:0007338 single fertilization
GO:0007339 binding of sperm to zona pellucida
GO:0007342 fusion of sperm to egg plasma membrane
GO:0007611 learning or memory
GO:0007612 learning
GO:0007632 visual behavior
GO:0008037 cell recognition
GO:0008306 associative learning
GO:0008542 visual learning
GO:0009314 response to radiation
GO:0009416 response to light stimulus
GO:0009566 fertilization
GO:0009988 cell-cell recognition
GO:0022412 cellular process involved in reproduction in multicellular organism
GO:0030534 adult behavior
GO:0035036 sperm-egg recognition
GO:0044708 single-organism behavior
GO:0044801 single-organism membrane fusion
GO:0045026 plasma membrane fusion
GO:0050890 cognition
GO:0061025 membrane fusion
Molecular Function GO:0004175 endopeptidase activity
GO:0004222 metalloendopeptidase activity
GO:0005178 integrin binding
GO:0008237 metallopeptidase activity
GO:0050839 cell adhesion molecule binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1187000: Fertilization
R-HSA-1300644: Interaction With The Zona Pellucida
R-HSA-1474165: Reproduction
Summary
SymbolADAM2
NameADAM metallopeptidase domain 2
Aliases PH-30b; PH30; CT15; cancer/testis antigen 15; FTNB; fertilin beta; CRYN1; CRYN2; PH30-beta; fertilin subunit ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ADAM2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolADAM2
NameADAM metallopeptidase domain 2
Aliases PH-30b; PH30; CT15; cancer/testis antigen 15; FTNB; fertilin beta; CRYN1; CRYN2; PH30-beta; fertilin subunit ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ADAM2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolADAM2
NameADAM metallopeptidase domain 2
Aliases PH-30b; PH30; CT15; cancer/testis antigen 15; FTNB; fertilin beta; CRYN1; CRYN2; PH30-beta; fertilin subunit ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ADAM2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1390.858
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1740.888
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1130.93
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.180.697
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.180.791
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.8140.0113
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ADAM2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277322.212.39.90.224
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275922.213.68.60.353
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21171923.5-4.51
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)862516.78.31
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.427.3-11.90.63
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolADAM2
NameADAM metallopeptidase domain 2
Aliases PH-30b; PH30; CT15; cancer/testis antigen 15; FTNB; fertilin beta; CRYN1; CRYN2; PH30-beta; fertilin subunit ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ADAM2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolADAM2
NameADAM metallopeptidase domain 2
Aliases PH-30b; PH30; CT15; cancer/testis antigen 15; FTNB; fertilin beta; CRYN1; CRYN2; PH30-beta; fertilin subunit ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ADAM2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ADAM2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolADAM2
NameADAM metallopeptidase domain 2
Aliases PH-30b; PH30; CT15; cancer/testis antigen 15; FTNB; fertilin beta; CRYN1; CRYN2; PH30-beta; fertilin subunit ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ADAM2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolADAM2
NameADAM metallopeptidase domain 2
Aliases PH-30b; PH30; CT15; cancer/testis antigen 15; FTNB; fertilin beta; CRYN1; CRYN2; PH30-beta; fertilin subunit ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ADAM2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolADAM2
NameADAM metallopeptidase domain 2
Aliases PH-30b; PH30; CT15; cancer/testis antigen 15; FTNB; fertilin beta; CRYN1; CRYN2; PH30-beta; fertilin subunit ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ADAM2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolADAM2
NameADAM metallopeptidase domain 2
Aliases PH-30b; PH30; CT15; cancer/testis antigen 15; FTNB; fertilin beta; CRYN1; CRYN2; PH30-beta; fertilin subunit ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ADAM2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.